Audit of brivaracetam in a secondary level epilepsy service.
Loading...
Authors
Rowe, Jacqui
Youssef, Carla
Tittensor, Phil
Manfredonia, Francesco
Issue Date
2019-09-29
Journal
Type
Conference Poster
Poster
Poster
Keywords
Audit
Brivaracetam
Epilepsy
Prescribing
Epilepsy services
Intellectual disability
Partners in Epilepsy
Antiepileptic drugs
Royal Wolverhampton NHS Trust
Shrewsbury and Telford Hospitals NHS Trust
Walsall Healthcare NHS Trust
Seizures
Brivaracetam
Epilepsy
Prescribing
Epilepsy services
Intellectual disability
Partners in Epilepsy
Antiepileptic drugs
Royal Wolverhampton NHS Trust
Shrewsbury and Telford Hospitals NHS Trust
Walsall Healthcare NHS Trust
Seizures
Journal Title
Volume
Issue
Begin page
End page
DOI
Abstract
Brivaracetam has shown efficacy and good tolerability and our experience suggests that it is a suitable add-on treatment for patients with refractory focal epilepsy. The very low rate of discontinuation for mood or behaviour reasons, particularly in the ID patients, indicates that it has the potential to be a positive choice for people with ID where issues have been noted on other medications, most notably Levetiracetam. In all three sites Brivaracetam has been on trust formulary for less than 18 months. These results are on the whole very positive but it would be important to revisit the data in 12 months to see if the initial positive results
are maintained long term. Another interesting study may be to look at using Brivaraceatam as an earlier
choice for add-on treatment. The majority of patients in this study had been tried on over 4 drugs prior to initiation of Brivaracetam.
Citation
Rowe, J. Youssef, C. Tittensor, P. Manfredonia, F. Smyth, C. Doherty, C. Audit of brivaracetam in a secondary level epilepsy service. . [Poster]. Exhibited at the Second Celebration of RWT Multidisciplinary Research and Innovation Event took place on 20th November 2019. Wolverhampton: The Royal Wolverhampton NHS Trust.MI_6025214_27.09.19_V_1.